Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database

Home » Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database

Journal: Immunology Res
Lead Author: Geier, et al.
Original date of publication: 02/01/2017
Link: https://pubmed.ncbi.nlm.nih.gov/27406735/

Summary Context

This paper found that HPV vaccine increased the likelihood of autoimmune events, including ovarian damage, lupus, and IBS.

Comments

This study found that irritable bowel syndrome (IBS), ovarian damage, lupus, and other autoimmune events were more common after receiving the HPV vaccine.

Abstract or Results, Key Passages

“It was observed that cases with the outcomes of gastroenteritis, rheumatoid arthritis, or thrombocytopenia, systemic lupus erythematosus, vasculitis, alopecia, CNS demyelinating conditions, ovarian damage, or irritable bowel syndrome were significantly more likely than controls to have received HPV4 vaccine.”

Keywords: adverse events HPV vaccine human papilloma virus IBS lupus ovaries

Full Author List: David A Geier , Mark R Geier

Previous PostLessons learnt in Japan from adverse reactions to the HPV vaccine: a medical ethics perspective
Next PostEvidence of Increase in Mortality After the Introduction of Diphtheria-Tetanus-Pertussis Vaccine to Children Aged 6-35 Months in Guinea-Bissau: A Time for Reflection?

Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database

Summary Context

Comments

Abstract or Results, Key Passages

Previous PostLessons learnt in Japan from adverse reactions to the HPV vaccine: a medical ethics perspective

Next PostEvidence of Increase in Mortality After the Introduction of Diphtheria-Tetanus-Pertussis Vaccine to Children Aged 6-35 Months in Guinea-Bissau: A Time for Reflection?